Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Blood stem cell procurement: donor safety issues

P Anderlini1, D Przepiorka, M Körbling

  • 1Department of Hematology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA.

Bone Marrow Transplantation
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-mismatched bone marrow transplantation in severe aplastic anemia.

Bone marrow transplantation·2017
Same author

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.

Bone marrow transplantation·2016
Same author

Sixty as the new forty: considerations on older related stem cell donors.

Bone marrow transplantation·2016
Same author

Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation.

Bone marrow transplantation·2016
Same author

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.

Bone marrow transplantation·2011
Same journal

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

Bone marrow transplantation·2026
Same journal

Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin's lymphoma.

Bone marrow transplantation·2026
Same journal

CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Bone marrow transplantation·2026
Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026
Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
See all related articles

Recombinant human granulocyte-colony stimulating factor (rhG-CSF) treatment and peripheral blood stem cell (PBSC) collection are safe for normal donors. Continued monitoring and standardized follow-up systems are recommended for PBSC donors.

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Cellular Therapy

Background:

  • Allogeneic transplantation of recombinant human granulocyte-colony stimulating factor (rhG-CSF)-mobilized peripheral blood stem cells (PBSCs) is increasingly common.
  • Safety considerations for healthy PBSC donors require comprehensive understanding and ongoing evaluation.

Purpose of the Study:

  • To review current data and emerging consensus on the safety of rhG-CSF treatment and PBSC collection in normal donors.
  • To provide guidance on rhG-CSF dosing, potential side effects, and donor eligibility criteria.

Main Methods:

  • Review of accumulating clinical experience and available data on rhG-CSF mobilization and PBSC collection.
  • Analysis of short-term safety profiles, dose-response relationships, and donor eligibility.

Related Experiment Videos

Main Results:

  • rhG-CSF treatment and PBSC collection demonstrate an acceptable short-term safety profile in normal donors.
  • rhG-CSF doses up to 10 microg/kg/day are effective for CD34+ cell mobilization with a manageable safety profile.
  • Transient cytopenias post-donation are common but generally self-limited; specific eligibility criteria are evolving.

Conclusions:

  • rhG-CSF mobilization and PBSC collection are generally safe for healthy donors, with acceptable short-term outcomes.
  • Standardized follow-up and data collection, potentially through an international registry, are crucial for long-term safety assessment.
  • Further research is needed to determine optimal rhG-CSF dosing and cost-effectiveness, as well as to define definitive contraindications.